260 Results

People

  1. Motzer
    Motzer
  2. Baselga
    Baselga
  3. Seidman
    Seidman
  4. Hudis
    Hudis
  5. Ilson
    Ilson
  6. O'Reilly
    O'Reilly
  7. Zelenetz
    Zelenetz
  8. Aghajanian
    Aghajanian
  9. Bajorin
    Bajorin
  10. Schwartz
    Schwartz

Groups

  1. Department of Medicine (207)
  2. Solid Tumor Oncology Division (174)
  3. Genitourinary Oncology Service (58)
  4. Breast Medicine Service (37)
  5. Hematologic Malignancies, Division of (34)
  6. Gastrointestinal Oncology Service (31)
  7. Survivorship Research (28)
  8. Center for Hematologic Malignancies (27)
  9. Gynecologic Medicine Service (22)
  10. Thoracic Oncology (20)
  1. "asthenia"
Formats
  1. Journal Article (251)
  2. Review (7)
  3. Conference Paper (1)
  4. Research Letter (1)
Groups
  1. Department of Medicine (207)
  2. Solid Tumor Oncology Division (174)
  3. Genitourinary Oncology Service (58)
  4. Breast Medicine Service (37)
  5. Hematologic Malignancies, Division of (34)
  6. Gastrointestinal Oncology Service (31)

More Groups

People
  1. Robert Motzer (38)
  2. Jose Baselga (13)
  3. Andrew Seidman (10)
  4. Clifford Hudis (9)
  5. David Ilson (9)
  6. Eileen O'Reilly (9)

More People

Years
  1. 2025 (8)
  2. 2024 (19)
  3. 2023 (13)
  4. 2022 (8)
  5. 2021 (12)
  6. 2020 (14)

More Years

Publications
  1. Journal of Clinical Oncology (24)
  2. Lancet Oncology (24)
  3. Annals of Oncology (15)
  4. Clinical Cancer Research (13)
  5. European Journal of Cancer (9)
  6. New England Journal of Medicine (9)

More Publications

Publishers
  1. Elsevier Inc. (42)
  2. Elsevier Science, Inc. (39)
  3. American Society of Clinical Oncology (26)
  4. Oxford University Press (25)
  5. Nature Publishing Group (17)
  6. Springer (15)

More Publishers

Results (260)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study
    Journal Article

    Javle, M.; Borad, M. J.; Azad, N. S.; Kurzrock, R.; Abou-Alfa, G. K.; George, B.; Hainsworth, J.; Meric-Bernstam, F.; Swanton, C.; Sweeney, C. J.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma
    Journal Article

    Bajorin, D. F.; Witjes, J. A.; Gschwend, J. E.; Schenker, M.; Valderrama, B. P.; Tomita, Y.; Bamias, A.; Lebret, T.; Shariat, S. F.; Park, S. H.; more...
    New England Journal of Medicine (2021)

    Fulltext@MSK | Save
  • EZH2 inhibition by tazemetostat: Mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma
    Review

    Julia, E.; Salles, G.
    Future Oncology (2021)

    Fulltext@MSK | Save
  • Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomised, phase 3 trial
    Journal Article

    Bellmunt, J.; Hussain, M.; Gschwend, J. E.; Albers, P.; Oudard, S.; Castellano, D.; Daneshmand, S.; Nishiyama, H.; Majchrowicz, M.; Degaonkar, V.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • RETRACTED: Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study
    Journal Article

    Rugo, H. S.; Lerebours, F.; Ciruelos, E.; Drullinsky, P.; Ruiz-Borrego, M.; Neven, P.; Park, Y. H.; Prat, A.; Bachelot, T.; Juric, D.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
    Journal Article

    Lee, N. Y.; Ferris, R. L.; Psyrri, A.; Haddad, R. I.; Tahara, M.; Bourhis, J.; Harrington, K.; Chang, P. M. H.; Lin, J. C.; Razaq, M. A.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Diffuse large B-cell lymphoma: New targets and novel therapies
    Review

    Cheson, B. D.; Nowakowski, G.; Salles, G.
    Blood Cancer Journal (2021)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma
    Journal Article

    Choueiri, T. K.; Powles, T.; Burotto, M.; Escudier, B.; Bourlon, M. T.; Zurawski, B.; Oyervides Juárez, V. M.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; more...
    New England Journal of Medicine (2021)

    Fulltext@MSK | Save
  • Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: Results from a multicenter, randomized, phase 2/3 study
    Journal Article

    Montesinos, P.; Roboz, G. J.; Bulabois, C. E.; Subklewe, M.; Platzbecker, U.; Ofran, Y.; Papayannidis, C.; Wierzbowska, A.; Shin, H. J.; Doronin, V.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: An open-label, multicentre, phase 1b study
    Journal Article

    O'Hara, M. H.; O'Reilly, E. M.; Varadhachary, G.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; Cabanski, C. R.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save